Emcure Pharmaceuticals Limited (BOM:544210)
India · Delayed Price · Currency is INR | Market Cap | 355.65B +38.2% |
| Revenue (ttm) | 96.83B +18.4% |
| Net Income | 10.11B +35.9% |
| EPS | 53.35 +35.6% |
| Shares Out | n/a |
| PE Ratio | 35.11 |
| Forward PE | 28.29 |
| Dividend | 3.60 (0.19%) |
| Ex-Dividend Date | Sep 4, 2026 |
| Volume | 2,872 |
| Open | 1,876.30 |
| Previous Close | 1,875.10 |
| Day's Range | 1,839.30 - 1,879.35 |
| 52-Week Range | 1,307.50 - 2,101.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 2,229.38 (+19.0%) |
| Earnings Date | Nov 3, 2026 |
About Emcure Pharmaceuticals
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynaecology, cardiovascular, blood-related, pain and analgesics, oncology/anti-neoplastics, anti-infectives, vitamins, minerals and nutrients, respiratory, HIV antivirals, Metabolics, gastro, anti-diabetic, neuro, derma, and mRNA vaccine. It provides its products under Orofer-Xt, Zostum, Bevon, Amaryl M, Orofer Fcm, Maxtra, Clexane, Metpure-Xl, Amaryl, Spegra, Feronia-Xt, Cardace, Pause, Lornit, Tar... [Read more]
Financial Performance
In fiscal year 2026, Emcure Pharmaceuticals's revenue was 92.04 billion, an increase of 16.56% compared to the previous year's 78.96 billion. Earnings were 9.24 billion, an increase of 35.67%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for 544210 stock is "Strong Buy." The 12-month stock price target is ₹2,229, which is an increase of 19.00% from the latest price.
News
Emcure Pharmaceuticals Slides: Investor presentation
Emcure Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
Emcure Pharmaceuticals Transcript: Q1 26/27
Q1 FY 2027 delivered 22.8% revenue growth and 35.4% PAT growth, driven by strong international and domestic performance, with EBITDA margin improving to 19.7%. Leadership changes, full ownership of Gennova, and robust R&D pipeline position the company for continued growth.
Emcure Pharmaceuticals Quarterly report: Q1 2027
Emcure Pharmaceuticals has published its Q1 2027 quarterly earnings report on August 6, 2026.
Emcure Pharmaceuticals Slides: Q1 2027
Emcure Pharmaceuticals has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 6, 2026.
Emcure Pharmaceuticals Transcript: Q4 25/26
FY 2026 saw 16.6% revenue growth, 41% adjusted PAT growth, and margin expansion, driven by strong international and resilient domestic performance. FY 2027 guidance is for low-to-mid-teen revenue growth and further margin gains, with Zuventus integration stabilizing.
Emcure Pharmaceuticals Quarterly report: Q4 2026
Emcure Pharmaceuticals has published its Q4 2026 quarterly earnings report on May 5, 2026.
Emcure Pharmaceuticals Slides: Q4 2026
Emcure Pharmaceuticals has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 5, 2026.
Emcure Pharmaceuticals Annual report: Q4 2026
Emcure Pharmaceuticals has published its Q4 2026 annual report on May 5, 2026.
Emcure Pharmaceuticals Transcript: Q3 25/26
Q3 FY26 saw 20.4% revenue growth and 48% PAT growth, driven by strong domestic and international performance, new launches, and margin expansion. Strategic partnerships, innovation, and government support for biologics position the company for sustained double-digit growth and margin improvement.
Emcure Pharmaceuticals Quarterly report: Q3 2026
Emcure Pharmaceuticals has published its Q3 2026 quarterly earnings report on February 4, 2026.
Emcure Pharmaceuticals Transcript: Q2 25/26
Q2 FY2026 saw 13% revenue growth and record profits, driven by strong domestic and international performance. Strategic moves included a Novo Nordisk partnership for Semaglutide and full Zuventus acquisition, with margin and debt targets updated following recent M&A.
Emcure Pharmaceuticals Quarterly report: Q2 2026
Emcure Pharmaceuticals has published its Q2 2026 quarterly earnings report on November 11, 2025.